We are live on ! Find out more
APLS

Apellis Pharmaceuticals
APLS

Delisted

APLS was delisted on the 13th of May, 2026.

Back to rankings

129 hedge funds and large institutions have $973M invested in Apellis Pharmaceuticals in 2019 Q3 according to their latest regulatory filings, with 43 funds opening new positions, 45 increasing their positions, 28 reducing their positions, and 12 closing their positions.

New
Increased
Maintained
Reduced
Closed

1,855% more call options, than puts

Call options by funds: $9.03M | Put options by funds: $462K

258% more first-time investments, than exits

New positions opened: 43 | Existing positions closed: 12

61% more repeat investments, than reductions

Existing positions increased: 45 | Existing positions reduced: 28

30% more funds holding

Funds holding: 99 → 129 (+30)

0% more funds holding in top 10

Funds holding in top 10: 3 → 3 (0)

0.6% less ownership

Funds ownership: 64% → 63.4% (-0.6%)

5% less capital invested

Capital invested by funds: $1.03B → $973M (-$52M)

Holders
129
Holders Change
+30
Holders Change %
+30.3%
% of All Funds
2.83%
Holding in Top 10
3
Holding in Top 10 Change
–
Holding in Top 10 Change %
–
% of All Funds
0.07%
New
43
Increased
45
Reduced
28
Closed
12
Calls
$9.03M
Puts
$462K
Net Calls
+$8.57M
Net Calls Change
+$8.56M

Top Buyers

Rank Fund Capital Flow
1
HA
HHLR Advisors
Cayman Islands
+$57.8M
2
Fidelity International
Fidelity International
Bermuda
+$30.2M
3
BC
Boxer Capital
California
+$19.3M
4
Millennium Management
Millennium Management
New York
+$18.4M
5
Morgan Stanley
Morgan Stanley
New York
+$11M

Top Sellers

Rank Fund Capital Flow
1
Wellington Management Group
Wellington Management Group
Massachusetts
-$41.7M
2
O
OrbiMed
New York
-$33M
3
Citadel Advisors
Citadel Advisors
Florida
-$16.3M
4
SAM
Sectoral Asset Management
Quebec, Canada
-$13.6M
5
Point72 Asset Management
Point72 Asset Management
Connecticut
-$10.2M
Name Holding Trade Value Shares
Change 		Change in
Stake
First Trust Advisors
51
First Trust Advisors
Illinois
$1.59M +$1.82M +66,006 New
SG Americas Securities
52
SG Americas Securities
New York
$1.58M +$1.81M +65,809 New
Susquehanna International Group
53
Susquehanna International Group
Pennsylvania
$1.52M +$780K +28,322 +81%
RhumbLine Advisers
54
RhumbLine Advisers
Massachusetts
$1.5M +$8.2K +298 +0.5%
Baird Financial Group
55
Baird Financial Group
Wisconsin
$1.45M -$142K -5,147 -8%
Rafferty Asset Management
56
Rafferty Asset Management
New York
$1.44M -$141K -5,124 -8%
HCM
57
Highbridge Capital Management
New York
$1.44M +$1.64M +59,664 New
WA
58
Whitebox Advisors
Minnesota
$1.27M +$1.45M +52,645 New
Lazard Asset Management
59
Lazard Asset Management
New York
$1.27M +$1.45M +52,655 New
CS
60
Credit Suisse
Switzerland
$1.24M +$628K +22,815 +79%
New York State Common Retirement Fund
61
New York State Common Retirement Fund
New York
$1.2M +$11K +400 +0.8%
SI
62
Sofinnova Investments
California
$1.19M – – –
SIM
63
Spark Investment Management
New York
$1.15M +$1.32M +47,900 New
PP
64
PDT Partners
New York
$1.15M +$294K +10,682 +29%
Barclays
65
Barclays
United Kingdom
$1.14M -$1.98M -71,889 -60%
PP
66
Paloma Partners
Connecticut
$1.13M +$1.29M +46,974 New
Wells Fargo
67
Wells Fargo
California
$1.09M +$40.7K +1,480 +3%
Squarepoint
68
Squarepoint
New York
$1.06M -$553K -20,103 -31%
TRSOTSOK
69
Teachers Retirement System of the State of Kentucky
Kentucky
$1.03M – – –
ECM
70
Element Capital Management
New York
$995K +$1.14M +41,291 New
Citigroup
71
Citigroup
New York
$865K -$305K -11,099 -24%
SO
72
STRS Ohio
Ohio
$814K +$930K +33,800 New
UBS AM
73
UBS AM
Illinois
$776K +$503K +18,292 +131%
Manulife (Manufacturers Life Insurance)
74
Manulife (Manufacturers Life Insurance)
Ontario, Canada
$749K +$6.83K +248 +0.8%
FAM
75
Fred Alger Management
New York
$747K +$771K +28,000 +933%
1 2
3
4 5

APLS Hedge Fund Activity: Q3 2019 in Review

129 of the 4,561 institutional investors tracked by Wall St. Rank reported a position in Apellis Pharmaceuticals (APLS) for Q3 2019, worth a combined $973M — down 5.1% from $1.03B a quarter earlier.

Buyers outnumbered sellers: 43 funds opened new APLS positions and 12 closed out — a net gain of 31 holders — while 45 added to existing stakes and 28 trimmed.

The largest buyer was HHLR Advisors, adding an estimated $57.8M. The largest seller was Wellington Management Group, cutting an estimated $41.7M.

  • 129 institutional investors held Apellis Pharmaceuticals (APLS) as of Q3 2019, up from 99 in Q2 2019.
  • Funds reported $973M of Apellis Pharmaceuticals stock for Q3 2019, down 5.1% quarter-over-quarter.
  • 43 funds opened new Apellis Pharmaceuticals positions in Q3 2019 and 12 closed out, a net change of +31 holders.
  • The largest Apellis Pharmaceuticals buyer in Q3 2019 was HHLR Advisors, an estimated $57.8M added.
  • The largest Apellis Pharmaceuticals seller in Q3 2019 was Wellington Management Group, an estimated $41.7M sold.

Based on aggregated 13F filings for Q3 2019.